Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. Click here to read ...

Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while ...

Citi analyst Yigal Nochomovitz maintained a Buy rating on Ligand Pharma today and set a price target of $390.00. Claim 55% Off TipRanks. Unlock powerful investing tools with TipRa ...

Ligand Pharmaceuticals Inc () has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks. Unlock powerful investing tools wit ...

Everest Medicines (HKEX 1952.HK, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Travere Therapeutics Inc. Annual cash flow by MarketWatch. View TVTX net cash flow, operating cash flow, operating expenses and cash dividends.

Everest Medicines (01952.HK) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of ...

Travere Therapeutics Inc. company and executive profile by Barron's. View the latest TVTX company infomation and executive bios.

Pricing for ETFs is the latest price and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you ...

In order to achieve this investment objective, the Fund will seek to track the performance of the Solactive Pharma Breakthrough Value Index Net Total Return (the “Index”). It will do so by investing ...